Investment
Features
FeesSafety
Academy
More
Pluang+

EverQuote posts 24% revenue growth, trades at discount amid insurer budget recovery and auto insurance focus

Market News
16 Oct 2026
Seeking Alpha
View Source
Bullish
EverQuote posts 24% revenue growth, trades at discount amid insurer budget recovery and auto insurance focus

EverQuote reported a 24% year-over-year revenue increase to $195.1 million in Q2, driven mainly by auto insurance which makes up 88% of its revenue, and a 35% growth in home insurance. The company benefits from recovering insurer marketing budgets and maintains a debt-free balance sheet. Despite trading at a forward P/E of 10.3x, significantly lower than its peers, concerns remain about the sustainability of insurer marketing spend and high revenue reliance on auto insurance and two major clients. These factors position EverQuote as a cyclical investment with growth potential but structural risks.

EverQuote's recent financial update provides context for readers interested in insurer spending and growth. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 16, 2026 20:11 WIB: Out of 142 priced Financials-sector US stocks tradable on Pluang, 83 rose and 48 fell today. Notable movers include KB Financial Group, Inc. at USD 119.93 with a 1-day change of +1.74%, Robinhood Markets, Inc. at USD 102.20 with Pluang order activity of 12% Sell / 88% Buy, and Lufax Holding Ltd at USD 0.90 with Pluang order activity of 100% Sell / 0% Buy.

More News

FDA approves phentolamine eye drops for presbyopia, offering a new treatment for age-related near vision loss.

FDA approves phentolamine eye drops for presbyopia, offering a new treatment for age-related near vision loss.

Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...

Market News
Bullish
42 minutes ago
K2 Vision performs 5,000 Light Adjustable Lens procedures, leading globally in this advanced vision tech.

K2 Vision performs 5,000 Light Adjustable Lens procedures, leading globally in this advanced vision tech.

K2 Vision has completed over 5,000 procedures using the Light Adjustable Lens (LAL), making it the highest-volume practice worldwide for this technology. The LAL is unique because it can be adjusted after implantation to fine-tune vision based on the...

Market News
Bullish
42 minutes ago
BlackRock's stake in Fagron drops below 3% after share transfers, holding 2.96% voting rights as of October 2026.

BlackRock's stake in Fagron drops below 3% after share transfers, holding 2.96% voting rights as of October 2026.

BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...

Market News
Neutral
42 minutes ago
BlackRock's stake in Fagron falls below 3% after share disposals, now holding 2.96% voting rights.

BlackRock's stake in Fagron falls below 3% after share disposals, now holding 2.96% voting rights.

BlackRock, Inc. disclosed that its shareholding in Fagron NV dropped below the 3% threshold to 2.96% after selling some voting securities, despite acquiring equivalent financial instruments. As of October 12, 2026, BlackRock holds 2,015,779 voting ri...

Market News
Neutral
42 minutes ago
Meridian International Center names 25 leaders shaping U.S. global influence across sectors in 2026 cohort

Meridian International Center names 25 leaders shaping U.S. global influence across sectors in 2026 cohort

Meridian International Center announced its inaugural New Architects of American Influence cohort, recognizing 25 leaders from business, technology, culture, sports, and government who are shaping U.S. global influence. The 2026 cohort includes leade...

Market News
Bullish
49 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App